Help wanted: A gig economy that works for everyone
05 September 2016
The three-year-old startup from LA that you may have never heard of was an on-demand laundry service. And among the growing number of on-demand service companies in the “gig economy,” it ranked as one of the oldest. But if you’re like most Americans, you probably know next to nothing about the “gig economy” that runs on companies like Washio.
05 September 2016
Diabetes is a chronic metabolic disease characterized by hyperglycemia (high blood glucose levels) that results from defects in insulin secretion, insulin action, or both. Chronic hyperglycemia in diabetic patients is associated with long-term damage, dysfunction and failure of multiple organs, including the eyes, kidneys, nerves, heart and blood vessels.
NIH review finds nondrug approaches effective for treatment of common pain conditions
05 September 2016
Data from a review of U.S.-based clinical trials published today in Mayo Clinic Proceedings suggest that some of the most popular complementary health approaches — such as yoga, tai chi, and acupuncture — appear to be effective tools for helping to manage common pain conditions. The review was conducted by a group of scientists from the National Center for Complementary and Integrative Health (NCCIH) at the National Institutes of Health.
Which European cities generate the biggest VC returns?
05 September 2016
With cities like London, Paris, Stockholm, Dublin and Barcelona in the mix, the hubs of VC activity in Europe represent centuries of international trade. But make no mistake, each city also represents an ecosystem fostering startups at every stage of development, along with the VC firms backing them.
Google DeepMind, NHS explore deep learning in head and neck cancer treatment
02 September 2016
Google DeepMind is partnering with England’s National Health Service to determine whether machine learning can streamline radiotherapy planning for head and neck cancers, freeing up clinicians’ time for patient care and research.
Breakthrough designation: Cornucopia or gold star?
02 September 2016
Since the FDA's breakthrough therapy designation came into existence as part of the FDA Safety and Innovation Act in July 2012, the agency has granted the designation to 145 drugs. The Center for Drug Evaluation and Research (CEDR) has fairly consistently granted the designation to about a third of the applications, while companies applying to the Center for Biologics Evaluation and Research (CBER) haven't quite known what to expect with the designation granted to just 8 percent of the applications in the 2013 fiscal year, the first full year companies could apply, to a high of 40 percent granted in fiscal 2015.
Third approval flows from U.S. biosimilar pipeline
02 September 2016
The FDA approved its third biosimilar Tuesday: Sandoz Inc.'s Erelzi, a biosimilar to Amgen Inc.'s Etanercept. As it has with the first two biosimilars, the agency approved an extrapolated label, licensing Erelzi for all of Etanercept's indications – rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis. The follow-on was tested in plaque psoriasis against the EU-licensed version of Enbrel, with a bridging study to the U.S. version.
Russia rises in global innovations ranking
01 September 2016
Russia ranked 48th in the 2016 Global Innovation Index (GII) , just ahead of Chile and Costa Rica and immediately after the United Arab Emirates and Turkey. In this year’s ranking Russia rose from the 56th place it occupied last year. Published annually by the Cornell University, the INSEAD Business School and the World Intellectual Property Organization in partnership with other institutions, the index ranks 128 nations by their capacity for, and success in, innovation.
Can pharma use Twitter Stickers to make community connections that bond?
01 September 2016
Ready to get sticky on Twitter, pharma? Twitter introduced stickers in June as a way for users to add fun visual expressions to their photos and connect back to the platform. Now it’s invited brands to the party.
CRO industry poised for steady growth as new work in China explodes
01 September 2016
The future looks good for the CRO industry. Not great or fantastic, but a lot better than it has been earlier in the decade. A new report out from KPMG notes that the industry appears headed for steady growth through 2019, with the largest organizations emerging from a major round of consolidation set to outperform the hundreds of smaller companies that still operate in biopharma. One of the big trends to look for here is a shift to China, where CRO work has been exploding. The CRO market was a modest $1.4 billion in 2007, but grew to $6.4 billion in ’14.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024